TY  - JOUR
AB  - As post-COVID complications, chronic respiratory diseases are one of the foremost causes of mortality. The quest for a cure for this recent global challenge underlines that the lack of predictive in vitro lung models is one of the main bottlenecks in pulmonary preclinical drug development. Despite rigorous efforts to develop biomimetic in vitro lung models, the current cutting-edge models represent a compromise in numerous technological and biological aspects. Most advanced in vitro models are still in the “proof-of-concept” phase with a low clinical translation of the findings. On the other hand, advances in cellular and molecular studies are mainly based on relatively simple and unrealistic in vitro models. Herein, the current challenges and potential strategies toward not only bioinspired but truly biomimetic lung models are discussed.
AU  - Doryab, A.
AU  - Groll, J.*
C1  - 67420
C2  - 54151
CY  - Postfach 101161, 69451 Weinheim, Germany
TI  - Biomimetic in vitro lung models: Current challenges and future perspective.
JO  - Adv. Mater.
VL  - 35
IS  - 13
PB  - Wiley-v C H Verlag Gmbh
PY  - 2023
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - Chronic wounds are characterized by delayed and dysregulated healing processes. As such, they have emerged as an increasingly significant threat. The associated morbidity and socioeconomic toll are clinically and financially challenging, necessitating novel approaches in the management of chronic wounds. Metal-organic frameworks (MOFs) are an innovative type of porous coordination polymers, with low toxicity and high eco-friendliness. Documented anti-bacterial effects and pro-angiogenic activity predestine these nanomaterials as promising systems for the treatment of chronic wounds. In this context, the therapeutic applicability and efficacy of MOFs remain to be elucidated. We, therefore, review structural-functional properties of MOFs and their composite materials and discuss how their multifunctionality and customizability could be leveraged as a clinical therapy for chronic wounds. This article is protected by copyright. All rights reserved.
AU  - Xiong, Y.*
AU  - Feng, Q.*
AU  - Lu, L.*
AU  - Qiu, X.*
AU  - Knoedler, S.
AU  - Panayi, A.C.*
AU  - Jiang, D.
AU  - Rinkevich, Y.
AU  - Lin, Z.*
AU  - Mi, B.*
AU  - Liu, G.*
AU  - Zhao, Y.*
C1  - 68043
C2  - 54521
CY  - Postfach 101161, 69451 Weinheim, Germany
TI  - Metal-organic frameworks and their composites for chronic wound healing: From bench to bedside.
JO  - Adv. Mater.
VL  - 36
IS  - 2
PB  - Wiley-v C H Verlag Gmbh
PY  - 2023
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - Lung fibrosis, as one of the major post-COVID complications, is a progressive and ultimately fatal disease without a cure. Here, we introduce an organ- and disease-specific in vitro mini-lung fibrosis model equipped with non-invasive real-time monitoring of cell mechanics as a functional readout. To establish an intricate multi-culture model under physiologic conditions, we developed a biomimetic ultrathin basement (BETA) membrane (<1 μm) with unique properties, including biocompatibility, permeability, and high elasticity (<10 kPa) for cell culturing under air-liquid interface (ALI) and cyclic mechanical stretch conditions. The human-based triple co-culture fibrosis model, which includes epithelial and endothelial cell lines combined with primary fibroblasts from idiopathic pulmonary fibrosis (IPF) patients established on the BETA membrane, is integrated into a millifluidic bioreactor system (CIVIC) with dose-controlled aerosolized drug delivery, mimicking inhalation therapy. We show the real-time measurement of cell/tissue stiffness (and compliance) as a clinical biomarker of the progression/attenuation of fibrosis upon drug treatment, which was confirmed for inhaled Nintedanib -an FDA-approved anti-fibrosis drug. The mini-lung fibrosis model allows the combined longitudinal testing of pharmacodynamics and pharmacokinetics of drugs, which is expected to enhance the predictive capacity of preclinical models and hence facilitate the development of approved therapies for lung fibrosis. This article is protected by copyright. All rights reserved.
AU  - Doryab, A.
AU  - Taskin, M.B.*
AU  - Stahlhut, P.*
AU  - Groll, J.*
AU  - Schmid, O.
C1  - 65965
C2  - 52821
TI  - Real-time measurement of cell mechanics as a clinically relevant readout of an in vitro lung fibrosis model established on a bioinspired basement membrane.
JO  - Adv. Mater.
VL  - 34
IS  - 41
PY  - 2022
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - Recent advances in 3D bioprinting allow for generating intricate structures with dimensions relevant for human tissue, but suitable bioinks for producing translationally relevant tissue with complex geometries remain unidentified. Here, a tissue-specific hybrid bioink is described, composed of a natural polymer, alginate, reinforced with extracellular matrix derived from decellularized tissue (rECM). rECM has rheological and gelation properties beneficial for 3D bioprinting while retaining biologically inductive properties supporting tissue maturation ex vivo and in vivo. These bioinks are shear thinning, resist cell sedimentation, improve viability of multiple cell types, and enhance mechanical stability in hydrogels derived from them. 3D printed constructs generated from rECM bioinks suppress the foreign body response, are pro-angiogenic and support recipient-derived de novo blood vessel formation across the entire graft thickness in a murine model of transplant immunosuppression. Their proof-of-principle for generating human tissue is demonstrated by 3D bioprinting human airways composed of regionally specified primary human airway epithelial progenitor and smooth muscle cells. Airway lumens remained patent with viable cells for one month in vitro with evidence of differentiation into mature epithelial cell types found in native human airways. rECM bioinks are a promising new approach for generating functional human tissue using 3D bioprinting.
AU  - De Santis, M.
AU  - Alsafadi, H.N.*
AU  - Tas, S.*
AU  - Bölükbas, D.A.*
AU  - Prithiviraj, S.*
AU  - Da Silva, I.A.N.*
AU  - Mittendorfer, M.*
AU  - Ota, C.
AU  - Stegmayr, J.*
AU  - Daoud, F.*
AU  - Königshoff, M.
AU  - Swärd, K.*
AU  - Wood, J.A.*
AU  - Tassieri, M.*
AU  - Bourgine, P.E.*
AU  - Lindstedt, S.*
AU  - Mohlin, S.*
AU  - Wagner, D.E.
C1  - 60767
C2  - 49531
CY  - Postfach 101161, 69451 Weinheim, Germany
TI  - Extracellular-matrix-reinforced bioinks for 3D bioprinting human tissue.
JO  - Adv. Mater.
VL  - 33
IS  - 3
PB  - Wiley-v C H Verlag Gmbh
PY  - 2021
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - On a daily basis, people are exposed to a multitude of health-hazardous airborne particulate matter with notable deposition in the fragile alveolar region of the lungs. Hence, there is a great need for identification and prediction of material-associated diseases, currently hindered due to the lack of in-depth understanding of causal relationships, in particular between acute exposures and chronic symptoms. By applying advanced microscopies and omics to in vitro and in vivo systems, together with in silico molecular modeling, it is determined herein that the long-lasting response to a single exposure can originate from the interplay between the newly discovered nanomaterial quarantining and nanomaterial cycling between different lung cell types. This new insight finally allows prediction of the spectrum of lung inflammation associated with materials of interest using only in vitro measurements and in silico modeling, potentially relating outcomes to material properties for a large number of materials, and thus boosting safe-by-design-based material development. Because of its profound implications for animal-free predictive toxicology, this work paves the way to a more efficient and hazard-free introduction of numerous new advanced materials into our lives.
AU  - Kokot, H.*
AU  - Kokot, B.*
AU  - Sebastijanović, A.*
AU  - Voss, C.
AU  - Podlipec, R.*
AU  - Zawilska, P.*
AU  - Berthing, T.*
AU  - Ballester-Lopez, C.
AU  - Danielsen, P.H.*
AU  - Contini, C.*
AU  - Ivanov, M.*
AU  - Krišelj, A.*
AU  - Čotar, P.*
AU  - Zhou, Q.
AU  - Ponti, J.*
AU  - Zhernovkov, V.*
AU  - Schneemilch, M.*
AU  - Doumandji, Z.*
AU  - Pušnik, M.*
AU  - Umek, P.*
AU  - Pajk, S.*
AU  - Joubert, O.*
AU  - Schmid, O.
AU  - Urbančič, I.*
AU  - Irmler, M.
AU  - Beckers, J.
AU  - Lobaskin, V.*
AU  - Halappanavar, S.*
AU  - Quirke, N.*
AU  - Lyubartsev, A.P.*
AU  - Vogel, U.*
AU  - Koklič, T.*
AU  - Stöger, T.
AU  - Štrancar, J.*
C1  - 60330
C2  - 49254
CY  - Postfach 101161, 69451 Weinheim, Germany
TI  - Prediction of chronic inflammation for inhaled particles: The impact of material cycling and quarantining in the lung epithelium.
JO  - Adv. Mater.
VL  - 32
PB  - Wiley-v C H Verlag Gmbh
PY  - 2020
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - Designed peptides derived from the islet amyloid polypeptide (IAPP) cross-amyloid interaction surface with Aβ (termed interaction surface mimics or ISMs) have been shown to be highly potent inhibitors of Aβ amyloid self-assembly. However, the molecular mechanism of their function is not well understood. Using solution-state and solid-state NMR spectroscopy in combination with ensemble-averaged dynamics simulations and other biophysical methods including TEM, fluorescence spectroscopy and microscopy, and DLS, we characterize ISM structural preferences and interactions. We find that the ISM peptide R3-GI is highly dynamic, can adopt a β-like structure, and oligomerizes into colloid-like assemblies in a process that is reminiscent of liquid–liquid phase separation (LLPS). Our results suggest that such assemblies yield multivalent surfaces for interactions with Aβ40. Sequestration of substrates into these colloid-like structures provides a mechanistic basis for ISM function and the design of novel potent anti-amyloid molecules.
AU  - Niu, Z.
AU  - Prade, E.*
AU  - Malideli, E.*
AU  - Hille, K.*
AU  - Jussupow, A.*
AU  - Mideksa, Y.G.*
AU  - Yan, L.M.*
AU  - Qian, C.*
AU  - Fleisch, M.
AU  - Messias, A.C.
AU  - Sarkar, R.
AU  - Sattler, M.
AU  - Lamb, D.C.*
AU  - Feige, M.J.*
AU  - Camilloni, C.*
AU  - Kapurniotu, A.*
AU  - Reif, B.
C1  - 65805
C2  - 52550
SP  - 5820-5830
TI  - Structural insight into IAPP-derived amyloid inhibitors and their mechanism of action.
JO  - Adv. Mater.
VL  - 59
IS  - 14
PY  - 2020
SN  - 0935-9648
ER  - 

TY  - JOUR
AB  - A functional cancer theranostic nanoplatform is developed, specifically tailored toward the optoacoustic modality by combining gold nanorods with DNA nanostructures (D-AuNR). DNA origami is used as an efficient delivery vehicle owing to its prominent tumor-targeting property. The D-AuNR hybrids display an enhanced tumor diagnostic sensitivity by improved optoacoustic imaging and excellent photothermal therapeutic properties in vivo.
AU  - Du, Y.*
AU  - Jiang, Q.*
AU  - Bézière, N.
AU  - Song, L.*
AU  - Zhang, Q.*
AU  - Peng, D.*
AU  - Chi, C.L.*
AU  - Yang, X.*
AU  - Guo, H.*
AU  - Diot, G.
AU  - Ntziachristos, V.
AU  - Ding, B.*
AU  - Tian, J.*
C1  - 49578
C2  - 40837
CY  - Weinheim
SP  - 10000-10007
TI  - DNA-nanostructure-gold-nanorod hybrids for enhanced in vivo optoacoustic imaging and photothermal therapy.
JO  - Adv. Mater.
VL  - 28
IS  - 45
PB  - Wiley-v C H Verlag Gmbh
PY  - 2016
SN  - 0935-9648
ER  -